Nivolumab-Induced Seronegative Encephalitis

Cabral, G; Ladeira, F; Gil, N

http://hdl.handle.net/10400.17/4811

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
J Neuroimmunol 2020.pdf		1.01 MB	Adobe PDF	Download

Send Feedback

Authors

Cabral, G

Ladeira, F

Gil, N

Abstract(s)

Immune checkpoint inhibitors (ICIs) have emerged as a new therapeutic tool for numerous types of cancer. Neurological complications have been reported in 1% of patients who have undergone checkpoint inhibition therapy. ICIs-induced encephalitides occur in 0.1-0.2% of patients within weeks after ICIs initiation; are usually seronegative and have nonspecific changes on imaging, CSF and electroencephalogram (EEG) studies. Early recognition and prompt treatment are important to prevent significant morbidity and mortality. We present a case of nivolumab-induced encephalitis with very subtle clinical symptoms and full recovery following ICIs suspension and steroids.

Keywords

HSAC NEU Aged Female Humans Encephalitis / blood Encephalitis / chemically induced* Encephalitis / diagnostic imaging* Immune Checkpoint Inhibitors / adverse effects* Nivolumab / adverse effects*